Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase NA 6Phase 1 3Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 46Thoracic 3Head & Neck 3Other hematologic neoplasm 2Gynecologic 2Genitourinary 2Sarcoma 1NET 1Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 15Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Prostatic Neoplasms 2Carcinoid Tumor 2Serotonin Syndrome 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Hypoglycemia 1Dumping Syndrome 1Disease 1Digestive System Neuroendocrine Tumor G1 1Colorectal Neoplasms 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Adenoma 1Acromegaly 1

Interventions

Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Pancreatic Neoplasms × NET × Clear all
NCT01525550 2019-07-30

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Pfizer

Phase 4 Completed
106 enrolled 26 charts
EndocrineGastrointestinalNET

Adenoma, Carcinoma, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡